The aim of this study was to assess the alterations in arterial stiffness by calculating CAVI, after therapy with anthracyclines, either with or without anti-HER2 therapy (trastuzumab +/− pertuzumab) in women with breast cancer. Here, ERBB2 is linked to breast cancer.